- Policy
- Big Pharma's sale of Old Drug has increased
- by Lee, Tak-Sun Dec 13, 2022 06:07am
- The number of domestic pharmaceutical companies acquiring domestic copyrights of original drugs has been increasing recently. This is a case in which domestic copyrights have also changed as most original developers sold global copyrights as part of restructuring. Jeil announced on the 8th that it will exclusively supply Bonviva and Bonviva p
- Policy
- Will SGLT2 combi benefit expansion eventually not happen?
- by Lee, Tak-Sun Dec 12, 2022 05:48am
- iDiscussions on the expansion of combined benefits between SGLT-2 drugs and other drugs continue to conflict. The government presented a voluntary cut rate to related companies last month to analyze their fiscal impact based on it, which is known to fall short of expectations. As a result, it is expected that it will soon be decided whether to
- Policy
- “Yoon admin’s healthcare policy reduces coverage"
- by Kim, Jung-Ju Dec 9, 2022 06:03am
- "Stop deceiving the public with an erroneous essential healthcare policy that lays the responsibility for wasteful spending of commercial healthcare to the patients. Civic groups related to healthcare united and strongly voiced their opposition to the essential healthcare measures that were announced by the government. The Korean Feder
- Policy
- Dong-A launches its first generic Dapapro
- by Lee, Tak-Sun Dec 8, 2022 06:05am
- Despite the patent dispute, Dong-A ST has released Dapapro, the first generic of SGLT-2 diabetes treatment Forxiga. Dapapro was listed for the upper limit of 684 won this month. According to industries on the 7th, Dong-A ST started selling with Dapapro salary registration. Dapapro is a prodrug product with a different chemical structure from
- Policy
- Only K-CAB continues to be applied refund-type PVA
- by Lee, Tak-Sun Dec 7, 2022 05:55am
- HK Inno.N’s ‘K-CAB Tab’ is the only drug that is applied the refund-type Price-Volume Agreement (PVA) system in Korea. The fact that the system is only applied to homegrown new drugs, and some companies do not prefer double pricing caused by refunds are pointed to as reasons for the low utilization rate of the PVA system. The Natio
- Policy
- Vaccine sales reached 3.4178 trillion won in Korea last year
- by Lee, Hye-Kyung Dec 7, 2022 05:55am
- About half of the companies complain of difficulties due to lack of funds in the research and commercialization process. Last year, domestic sales in the vaccine industry totaled 3.4178 trillion won and exports amounted to 628.7 billion won. The Ministry of Health and Welfare (Minister Cho Kyu-hong) and the Ministry of Trade, Industry, and
- Policy
- Reimb of antidiabetic SGLT-2+DPP-4 combo near
- by Kim, Jung-Ju Dec 7, 2022 05:55am
- Expanding reimbursement to the combined use of SGLT-2 inhibitors and DPP-4 inhibitors as treatment for diabetes has entered its final stages. As the reimbursement will be carried out through voluntary price cuts by pharmaceutical companies as intended by the government, the process may proceed faster than when companies take the drug pri
- Policy
- One-shot Zolgensma fulfills terms of its RSA contract
- by Kim, Jung-Ju Dec 6, 2022 05:57am
- Zolgensma (onasemnogene abeparvovec), the ultra-high-priced ‘one-shot treatment’ that succeeded in receiving reimbursement in Korea in May this year, will start fulfilling the terms of its risk-sharing agreements (RSA) contract. If the drug was administered at the time its reimbursement was approved in Korea, the medical institutions t
- Policy
- The government is conducting six studies on drug prices
- by Kim, Jung-Ju Dec 6, 2022 05:57am
- With a number of drug price systems in operation within the positive list system, the government is conducting six studies on drug price policies related to insurance benefit entry permits and follow-up management, drawing attention to how the results will be reflected next year. According to the Ministry of Health and Welfare, this year, the
- Policy
- "A9 countries not used for drug pricing reevals next year"
- by Kim, Jung-Ju Dec 5, 2022 05:53am
- The government announced that it will not immediately apply its plan to increase the number of foreign drug price reference countries by 2 in its reevaluations next year. The foreign reference drug pricing system is essentially used to evaluate the price of reimbursed drugs in Korea. Also, regarding the pharma-bio industry’s concern, the
